| Numéro |
EPJ Web Conf.
Volume 153, 2017
ICRS-13 & RPSD-2016, 13th International Conference on Radiation Shielding & 19th Topical Meeting of the Radiation Protection and Shielding Division of the American Nuclear Society - 2016
|
|
|---|---|---|
| Numéro d'article | 04006 | |
| Nombre de pages | 5 | |
| Section | 4. Medical Facilities, Radiotherapy & Medical Applications, Space Dosimetry & Shielding | |
| DOI | https://doi.org/10.1051/epjconf/201715304006 | |
| Publié en ligne | 25 septembre 2017 | |
https://doi.org/10.1051/epjconf/201715304006
A Shielding Concept for the MedAustron Facility
1 EBG MedAustron GmbH, Austria
2 CERN, HSE-RP, Geneva 23, CH-1211 Geneva, Switzerland
* Lukas.Jaegerhofer@medaustron.at
Published online: 25 September 2017
MedAustron is a synchrotron based accelerator facility for cancer therapy and research in Wiener Neustadt, 50 km south of Vienna. The facility will provide protons up to kinetic energies of 250 MeV and carbon ions up to 400 MeV/n for ion beam therapy. Additionally, protons up to 800 MeV kinetic energy will be used in a dedicated room for non-clinical research. In order to obtain a shielding concept for this facility a detailed geometry of the accelerator facility was implemented into the Monte-Carlo code FLUKA and shielding simulations were performed. In the course of these simulations the contributions of different particle types to the mixed fields around the accelerator and behind shielding were analysed. In an iterative process with the architect the final design of the shielding concept was developed until it was capable of reducing the effect of secondary radiation on humans and the environment below Austrian legal limits.
Key words: EBG MedAustron GmbH / Shielding Calculations / Hadron Therapy / FLUKA
© The Authors, published by EDP Sciences, 2017
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.